Menu

17/10/12: Barcode Crosstalk can Severely Affect Next Generation Sequencing Results

I often tell my customers that Integrated DNA Technologies (IDT, www.idtdna.com) is the “best oligo house in the world.” However, because I operate in Denmark and Sweden, where many customers have not even heard of IDT, I usually get the response that (yeah, yeah) this is because I am trying to sell IDT oligos. Which must be partly true, since I can hardly claim to be unbiased. However, when you consider that no other company does 100% QC on its oligos (and can demonstrate that systematically to customers), has advanced oligonucleotide synthesis chemistry, whilst reducing prices and delivering fast turnaround times, I think I am on pretty solid ground. However, in addition to those things that “IDT is known for” (assuming you have heard of them), is their innovation in the use of chemically synthesized DNA.

Earlier this year, IDT released gBlocks, driving costs down and increasing turnaround time for synthetic biologists. However, the subject of this post is another recent innovation: IDT’s TruGrade™ Processing Service.

The TruGrade™ Processing Service is a proprietary production process that reduces the risk of oligonucleotide crosstalk during multiplex next generation sequencing applications. Oligo crosstalk is a potential cause of barcode misalignment, which can lead to inaccurate conclusions by associating sequencing data with the wrong sample.

Oligonucleotides manufactured using the TruGrade service are suitable for:

  • Sample preparation using barcoded adapters for multiplex sequencing 
  • PCR using barcoded fusion primers for multiplex amplicon sequencing

The title of this post refers to an article that explains why standard oligonucleotide synthesis for NGS applications might lead to sample “crosstalk” when multiplexing, and how this can be reduced by using TruGrade™ Processing Service for your oligos. The article can be accessed here:

Barcode Crosstalk can Severely Affect Next Generation Sequencing Results

Comments are closed.